---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-054309"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:12:34.543240+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Alaunos directors convert $139K deferred fees to equity: shares + options

## Summary
- Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.
- Issued 38,269 common shares with aggregate fair value of $111,750.
- Granted 10,904 fully vested stock options at $2.92 exercise price, aggregate fair value $27,250.
- Board elected equity over cash under Non-Employee Directors Compensation Policy.

## SEC filing metadata
- accession: 0000950170-25-054309
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/0000950170-25-054309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000095017025054309/tcrt-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-054309
- JSON: https://secwatch.observer/filing/0000950170-25-054309.json
- Plain text: https://secwatch.observer/filing/0000950170-25-054309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.